Ashwagandha for Depression: Dosage, Research, and What to Expect

March 31, 2026Mental Health

Depression is a complex condition with no single solution, and anyone searching for help deserves an honest accounting of what works, what might help, and what remains uncertain. Ashwagandha (Withania somnifera) has attracted growing interest as a potential complementary approach for depressive symptoms, but the research is still early. Here is what we know so far, what dosage the studies have used, and what a realistic timeline for effects looks like.

What the Research Shows

The most relevant clinical trial for ashwagandha and depression is the Lopresti 2017 study, published in the Journal of Affective Disorders. In this 12-week randomized, double-blind, placebo-controlled trial, 66 adults with moderate-to-severe depression received either 600 mg per day of a high-concentration ashwagandha extract or placebo, both as an adjunct to their existing standard treatment.

The ashwagandha group showed significantly greater reductions in depression scores (measured by the Hamilton Depression Rating Scale) and anxiety scores compared to the placebo group. Cortisol levels, a biomarker of chronic stress, also decreased more in the ashwagandha group. These results are encouraging, but several points of context matter: the sample size was small, participants were already receiving conventional treatment, and this remains one of only a few dedicated trials on ashwagandha for depression.

Broader systematic reviews have noted that ashwagandha may have mild antidepressant-like effects across multiple studies, but the overall evidence base is not yet strong enough to support standalone clinical recommendations. More and larger trials are needed.

The BDNF and Neuroplasticity Connection

One of the more intriguing lines of research involves brain-derived neurotrophic factor (BDNF), a protein that plays a central role in neuroplasticity, the brain's ability to form new neural connections and adapt over time. Reduced BDNF levels have been consistently associated with depression, and many effective antidepressant treatments, including SSRIs and ketamine therapy, appear to increase BDNF expression.

Preclinical studies suggest that ashwagandha and its active compounds may support BDNF levels and promote neuroplasticity. Animal models have shown that withanolide administration can increase BDNF in the hippocampus, a brain region closely linked to mood regulation. This is a plausible biological pathway through which ashwagandha could influence depressive symptoms, though it is important to emphasize that animal findings do not always translate to humans. Clinical trials measuring BDNF changes in humans taking ashwagandha are still limited.

This neuroplasticity angle is worth noting because it parallels mechanisms seen in other mental health treatments. Ketamine, for instance, produces rapid antidepressant effects partly through BDNF-mediated neuroplasticity and anti-inflammatory pathways. Ashwagandha's effects, if confirmed in humans, would likely be far more modest in magnitude and slower in onset, but the shared biological theme is interesting from a research perspective.

Dosage: What the Studies Used

The clinical trials that have reported positive results for mood and depression have generally used the following parameters:

Dose range: 300 to 600 mg per day of a standardized root extract.
Extract type: Most studies used high-concentration, full-spectrum extracts standardized to withanolide content. KSM-66 and Sensoril are the two most widely researched branded extracts. KSM-66 is standardized to at least 5% withanolides; Sensoril is standardized to a minimum of 10% withanolide glycosides.
Dosing schedule: Typically split into two daily doses (for example, 300 mg in the morning and 300 mg in the evening), though some trials used a single daily dose.
Duration: Most trials lasted 8 to 12 weeks before significant effects were observed.

Using a standardized extract matters. Raw ashwagandha powder can vary widely in active compound concentration from batch to batch, making it difficult to know what dose you are actually getting. If you choose to try ashwagandha, select a product from a reputable manufacturer with third-party testing. For more on choosing a safe product and understanding potential risks, see our guide to ashwagandha side effects and safety.

What to Realistically Expect

Ashwagandha is not a fast-acting intervention. Unlike ketamine therapy, which can produce noticeable mood shifts within hours to days in some individuals, ashwagandha's effects, if they occur, tend to emerge gradually over several weeks. Most trial participants did not report meaningful changes until at least 4 to 6 weeks of consistent use, with full effects measured at the 8- to 12-week mark.

If you are currently experiencing moderate-to-severe depression, ashwagandha should not be your primary or sole treatment. The available evidence supports it only as a potential adjunct to conventional care, not as a standalone therapy. If you are considering it, discuss it with your provider so they can weigh it against your current treatment plan and monitor for any interactions with existing medications.

The Bottom Line

Ashwagandha shows preliminary promise as a complementary support for depressive symptoms, particularly when used alongside standard treatment. However, the evidence is still early, and it should not replace professional mental health care. If you are interested in trying it, use a standardized extract at a researched dose and work with your healthcare provider.